Molina Healthcare’s first quarter results were marked by disciplined medical cost management and ongoing adaptation to a shifting Medicaid landscape. CEO Joseph Zubretsky described the quarter as “solid under the circumstances,” emphasizing the company’s 91.1% consolidated medical cost ratio and a 1.6% adjusted pretax margin. Management attributed performance to favorable medical cost trends and effective protocols in response to last year’s higher acuity shifts from Medicaid redeterminations. Zubretsky noted, “Our expectation that the acuity shift trend that we had experienced in 2025 was behind us and would not recur is holding up.”
Is now the time to buy MOH? Find out in our full research report (it’s free for active Edge members).
Molina Healthcare (MOH) Q1 CY2026 Highlights:
- Revenue: $10.8 billion vs analyst estimates of $10.83 billion (3.1% year-on-year decline, in line)
- Adjusted EPS: $2.35 vs analyst estimates of $1.91 (23% beat)
- Adjusted EBITDA: $257 million vs analyst estimates of $210.4 million (2.4% margin, 22.1% beat)
- The company dropped its revenue guidance for the full year to $42 billion at the midpoint from $44.5 billion, a 5.6% decrease
- Management reiterated its full-year Adjusted EPS guidance of $5 at the midpoint
- Operating Margin: 0.8%, down from 3.9% in the same quarter last year
- Customers: 5.03 million, down from 5.49 million in the previous quarter
- Market Capitalization: $9.66 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Molina Healthcare’s Q1 Earnings Call
-
Andrew Mok (Barclays): asked for detail on state-level Medicaid attrition and its impact on medical loss ratio outlook. CEO Joseph Zubretsky and CFO Mark Keim explained that higher attrition in states like California is offset by a more stable remaining population, minimizing further acuity shifts.
-
Ann Hynes (Mizuho Securities): inquired about free cash flow sustainability and debt to capital targets. Keim highlighted strong parent-level cash flow and reiterated the goal to maintain debt to capital in the low 40% range, with current levels deemed comfortable.
-
Kevin Fischbeck (Bank of America): questioned the decision to reaffirm rather than raise guidance. Zubretsky described the approach as prudent, citing the need for “time-tested” validation after volatility in prior quarters and no unusual items impacting Q1 results.
-
Scott Fidel (Goldman Sachs): sought clarification on Medicare segment profitability as Molina exits the MAPD product. Zubretsky and Keim provided detail on the duals product mix and noted that earnings drag from MAPD will disappear next year, improving segment profitability.
-
John Stansel (JPMorgan): asked about the M&A pipeline and whether recent Medicaid plan exits affect Molina’s acquisition strategy. Zubretsky confirmed the pipeline remains active and that M&A remains a core strategic lever, with more detail to come at Investor Day.
Catalysts in Upcoming Quarters
In upcoming quarters, our analysts will be watching (1) the pace and magnitude of Medicaid rate increases and how states implement work or community engagement requirements, (2) margin performance as Molina shifts its product mix and executes on new dual-eligible and Florida CMS contracts, and (3) the sustainability of medical cost trends and any signs of renewed volatility in utilization. The trajectory of M&A activity and further regulatory developments will also be critical areas of focus.
Molina Healthcare currently trades at $183.09, up from $153 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
